WO2023230535A1 - Scaffold for regenerative organization of prosthetic organ tissue and method - Google Patents
Scaffold for regenerative organization of prosthetic organ tissue and method Download PDFInfo
- Publication number
- WO2023230535A1 WO2023230535A1 PCT/US2023/067435 US2023067435W WO2023230535A1 WO 2023230535 A1 WO2023230535 A1 WO 2023230535A1 US 2023067435 W US2023067435 W US 2023067435W WO 2023230535 A1 WO2023230535 A1 WO 2023230535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compartments
- physical vapor
- vapor depositing
- organ tissue
- tissue scaffold
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 49
- 210000000056 organ Anatomy 0.000 title claims abstract description 44
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 28
- 230000008520 organization Effects 0.000 title abstract description 5
- 238000000151 deposition Methods 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 210000000130 stem cell Anatomy 0.000 claims description 24
- 239000002407 tissue scaffold Substances 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 19
- 210000002744 extracellular matrix Anatomy 0.000 claims description 13
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 230000002792 vascular Effects 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 230000003511 endothelial effect Effects 0.000 claims description 7
- 239000000919 ceramic Substances 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 238000010899 nucleation Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 229910045601 alloy Inorganic materials 0.000 claims description 5
- 239000000956 alloy Substances 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 4
- 238000004544 sputter deposition Methods 0.000 claims description 3
- -1 pseudometal Substances 0.000 claims 3
- 230000004640 cellular pathway Effects 0.000 claims 2
- 238000005240 physical vapour deposition Methods 0.000 abstract description 3
- 230000009469 supplementation Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 12
- 238000013461 design Methods 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 239000012620 biological material Substances 0.000 description 10
- 239000010408 film Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010004 neural pathway Effects 0.000 description 3
- 210000000118 neural pathway Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000000275 quality assurance Methods 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical group [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000004377 microelectronic Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000008883 Patent Foramen Ovale Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000011852 carbon nanoparticle Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000037234 cartilage building Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000018747 cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000313 electron-beam-induced deposition Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001659 ion-beam spectroscopy Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000007734 materials engineering Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002294 plasma sputter deposition Methods 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 229910002059 quaternary alloy Inorganic materials 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229910000601 superalloy Inorganic materials 0.000 description 1
- 229910002058 ternary alloy Inorganic materials 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/141—Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/0086—Special surfaces of prostheses, e.g. for improving ingrowth for preferentially controlling or promoting the growth of specific types of cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
Definitions
- the second provides largely artificial substitutes, functionally ready to ameliorate or replace the role of an organ (3).
- the aim of this invention is to provide mechanisms for designing prosthetic organ tissue as a scaffold for regenerative organization of organ tissue for organ function supplementation or replacement.
- Fig. l is a diagram of a radially disposed, stacked arrangement of a multi-cell prosthetic extracellular matrix (PECM) having centrally located channels.
- PECM prosthetic extracellular matrix
- Fig. 2 is an electron micrograph of a current commercial stent at 250X magnification illustrating high degrees of surface irregularity and multiple foreign material inclusions with elongated defects along the long axis of the struts.
- FIG. 3 is an illustration of endothelial cells migrating along microscopic, high definition grooves.
- Fig. 4 is an illustration depicting additive physical vapor deposited (PVD) nitinol by orderly nickel and titanium atom deposition from a high energy plasma.
- PVD physical vapor deposited
- FIG. 5 is an illustration depicting a conceptual prosthetic eye in which electronic output from miniature high-performance cameras elicit image perception when coupled with optic nerve tissue using the PECM of the present invention.
- first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms may be only used to distinguish one element, component, region, layer or section from another region, layer or section. Terms such as “first,”’ “second,”’ and other numerical terms when used herein do not imply a sequence or order unless clearly indicated by the context. Thus, a first element, component, region, layer or section discussed below could be termed a second element, component, region, layer or section without departing from the teachings of the exampie embodiments.
- Spatially relative terms such as “inner,” “outer,” “beneath,” “below,” “lower,” “above,” “upper,” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. Spatially relative terms may be intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below'”, or “beneath” other elements or features would then be oriented “above'” the other elements or features. Thus, the example term “below” can encompass both an orientation of above and below The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly .
- substantially is intended to mean a quantity, property, or value that is present to a great or significant extent and less than, more than or equal to total.
- substantially vertical may be less than, greater than, or equal to completely vertical.
- “About” is intended to mean a quantity, property, or value that is present at ⁇ 10%. Throughout this disclosure, the numerical values represent approximate measures or limits to ranges to encompass minor deviations from the given values and embodiments having about the value mentioned as well as those having exactly the value mentioned. Other than in the working examples provided at the end of the detailed description, all numerical values of parameters (e g., of quantities or conditions) in this specification, including the appended claims, are to be understood as being modified in all instances by the term “about” whether or not “about” actually appears before the numerical value. “About” indicates that the stated numerical value allows some slight imprecision (with some approach to exactness in the value; approximately or reasonably close to the value; nearly).
- references to “embodiment” or “variant”, e.g., “one embodiment,” “an embodiment,” “example embodiment,” “various embodiments,” etc., may indicate that the embodiment s) or variant(s) of the invention so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment,” or “in an exemplary embodiment,” do not necessarily refer to the same embodiment or variant, although they may.
- the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
- material is intended to refer to elemental metals, alloyed metals or pseudometals.
- pseudometallic and “pseudometallic” are intended to mean materials which exhibit material characteristics substantially the same as metals.
- pseudometallic materials include, without limitation, composite materials, polymers, and ceramics.
- Composite materials are composed of a matrix material reinforced with any of a variety of fibers made from ceramics, metals, carbon, or polymers.
- layer is intended to mean a substantially uniform material limited by interfaces between it and adjacent other layers, substrate, or environment. The interface region between adjacent layers is an inhomogeneous region in which extensive thermodynamic parameters may change.
- Different layers are not necessarily characterized by different values of the extensive thermodynamic parameters but at the interface, there is a local change at least in some parameters.
- the interface between two steel layers that are identical in composition and microstructure may be characterized by a high local concentration of grain boundaries due to an interruption of the fdm growth process.
- the interface between layers is not necessarily different in chemical composition if it is different in structure.
- build axis or “build direction” is intended to refer to the deposition axis in the material. For example, as a material is being deposited onto a substrate, the thickness or Z-axis of the material being deposited will increase, this is the build axis of the material.
- circumferential or “circumferential axis” is intended to refer to the radial direction of a tubular, cylindrical or annular material or to the Y-axis of a polygonal material.
- longitudinal longitudinal axis
- tube axis are intended to refer to an elongate aspect or axis of a material or to the X-axis of the material.
- bulk material is intended to refer to the entirety of the material between its surfaces.
- film is intended to encompass both thick and thin films and includes material layers, coatings and/or discrete materials regardless of the geometric configuration of the material.
- thick film is intended to mean a film or a layer of a film having a thickness greater than 10 micrometers.
- thin film is intended to mean a film or a layer of a film having a thickness less than or equal to 10 micrometers.
- PVD physical vapor deposition
- sputtering electron-beam deposition, hot-boat evaporation, reactive evaporation, ion platting, plasma sputtering and/or ion beam sputtering.
- Implantable devices are currently common tools of practice in several medical specialties: Ocular lens implants have been time-proven in ocular surgery (4) and cochlear implants are becoming increasingly sophisticated (5). Cardiac pacemakers and ICD (implantable cardioverter defibrillator), are probably the most successful standalone microelectronic implants so far (6). In orthopedic surgery, rehabilitation of knee function due to osteochondral degenerative changes currently uses both approaches: intra capsular introduction of cartilage building promoters (7) and total artificial joint replacement (8).
- Implantable cardiovascular prosthetics have been very effective and enjoy a long history of successful development: Surgical and transluminal vascular grafts and stent grafts and prosthetic cardiac valves (11), caval filters (12) coronary stents (13,14) , patent foramen ovale occluders (15), atrial appendage closure devices (16) mitral valve repair clip (17), transluminal aortic valve replacement (18) among many others, already available or in development.
- Bioresorbable vascular stents can be considered a regenerative approach insofar as the theory upon which they are based. Founded on the assumption that the diseased vascular wall tissues would reorganize into functional structures, vasomotion and positive remodeling was expected concurrently with the disappearance of the scaffold (24). Although the BRS proved equivalent to drug eluting metal stents in pivotal randomization trials (25) they have been clinically abandoned as post-approval clinical evidence cast doubts about their safety and efficacy (26). Some late thrombotic events with the BRS coincided in time with complete scaffold reabsorption supporting the notion that a permanent stent scaffold may be needed to replace the loss of the arterial connective structure. This is an important component of atherosclerotic vascular occlusive disease as the vessel structure supports endothelial cell function and stability (27).
- Progenitor stem cells as the building blocks for regenerative therapies of solid organs.
- Progenitor stem cells from fetal tissues, umbilical cord, bone marrow, or fibroblast cell lines (28) can be induced to produce mature lineage cells as neural, hepatic, cardiac, renal and so forth (29). This brought about a large and ongoing body of research based on the possibility of regeneration of organs for in vitro or in vivo applications (30).
- Engineered prosthetic cellular scaffolds may be more realistic tissue platforms as conceptualized by constructs such as suggested in Figs. 1A-1C.
- Figure 1A and IB illustrates a radially disposed, stacked arrangement of a multicellular prosthetic extra cellular matrix (PECM) 10 in accordance with the present invention.
- the PECM includes individual modules 12 interconnected along their Z-axis by centrally located channels 14 that extend along a longitudinal axis of the PECM 10 for vascular supply to and drainage from the cells for a plurality of compartments 16 on each individual PECM module 12.
- Each individual module 12 may be formed as a coherent fdm and then assembled as a multi-layer structure of coherent films or, alternatively, as a layer in a multi-layer film of biomaterial.
- Fig. IB illustrates the Z-axis stacked array of the individual modules 12 forming the PECM.
- Fig. 1C illustrates an individual compartment 16, with a plurality of microgrooved channels 18 communicating between other compartments 18 the plurality of compartments. Also shown in Fig. 1C are cells 19 that are either seeded onto the compartments 18 or migrated to a compartment.
- Prosthetic scaffolds may be more plausible as engineered extracellular matrices may guide cell growth, location and differentiation to achieve the goal of functional semisynthetic organs. Progenitor cell seeding into or onto the extracellular matrix of the prosthetic scaffold may further be performed to enhance populating of the extracellular matrix.
- Progenitor cell seeding into or onto the extracellular matrix of the prosthetic scaffold may further be performed to enhance populating of the extracellular matrix.
- Organ transplantation of live or decellularized tissue may not be considered regenerative therapy since the transplanted organ or parts of an organ, whether it be a homograft, allograft or xenograft is functionally developed and aims at readily substitute a diminished or absent function.
- live donor transplant is well tolerated by the recipient provided MHC, HLA, ABO compatibility, adjuvant chemotherapy and prevention of infection and other potentially adverse events (37).
- allogenic or autologous transplants of blood precursors in the bone marrow routinely restore blood cell production in patients with bone marrow depletion by chemo or radiation therapy.
- bone marrow cells are among human tissues of rapid growth that provide for the attrition of their end-of-the-line constituents and, their spontaneous differentiation is actually pre-determined, not manipulated and, or induced. Same applies to skin and biological cardiac valves. Corneal transplants, ligaments, bone and cartilage grafts should be considered developed tissues with full functional capability like the lung, pancreas, kidney, liver and heart. Therefore, they fall outside of the frame that define regenerative therapies.
- FIG. 1 is an electron micrograph illustrating such features in a commercially available vascular stent. It has been demonstrated that such surface irregularities and foreign material inclusions are impede or even prevent cellular attachment and proliferation on the material surfaces resulting in either incomplete or non-incorporation of the devices into the biological tissue. As such, current materials are sub-optimal as prosthetic tissue scaffolds, particular for organ tissue regeneration.
- Controlled nanofabrication on artificial surfaces allows for micro-engineering of prosthetic surfaces in a manner that is highly controllable.
- Working on micro-engineering of the surface of implantable vascular stents materials new techniques for fabrication of high definition microgrooves have been developed. The goal was to increase the migration speed and influence growth direction of human aortic endothelial cells to accelerate colonization and therefore positively influence the prosthetic healing process.
- Engineered micro-grooves have been made that are within the size range of vascular endothelial cells (EC). An effort was made to maintain the features definition within few hundred nanometers.
- Figure 3 depicts a portion of a biomaterial, for example, a biomaterial that makes up a portion of the PECM modules 12 of the inventive organ tissue scaffold 10.
- Endothelial or other cells 24 directionally migrate along the microscopic, high-definition grooves 22 in surfaces of the biomaterial. In this manner, cells 24 can proliferate and migrate along the grooves 22 to populate the compartments 16 of each module 10 in the PECM tissue scaffold 10.
- the grooves directional guide the proliferation and migration of the cells, increasing their translation speed and their ability to more rapidly colonize a surface of the PECM biomaterial and compartments 16.
- Additive PVD achieves an orderly deposition of metal or pseudometal atoms from a high energy plasma.
- Figure 4 is an illustration at of this orderly deposition of nitinol from nickel and titanium atoms.
- PVD process are highly controllable to yield predictive material properties in the resulting deposited material.
- the structures of the deposited materials may have complex geometries based upon the geometry of the substrate onto which the deposition occurs.
- the cellular scaffold elements of the inventive PECM may be formed by PVD processes by vacuum depositing the desired metal or pseudometal onto substrates having geometries corresponding to the desired shape of the cellular scaffold elements. It will be understood, of course, that other metals or pseudometals may be vacuum deposited, such as cobalt-chromium alloys, stainless steel, ternary or quaternary alloys, or the like.
- Figure 5 illustrates a conceptual depiction of a prosthetic eye that employs high- performance camera(s) as part of the eye prosthesis.
- the electrical output from the cameras must communicate with the optical neural pathways.
- Such communication is made possible by constructing a multi-cellular PECM of the present invention, seeding or growing nerve cells as an optical neural pathway onto the PECM to conduct electrical signals from the camera(s) of the prosthetic eye to the optic nerve or other neural pathway to the brain.
Abstract
Prosthetic scaffold for regenerative organization of organ tissue for organ function supplementation or replacement and a method for making the prosthetic scaffold by physical vapor deposition of same.
Description
Title:
[0001] Scaffold for Regenerative Organization of Prosthetic Organ Tissue and Method
Background of the Invention
[0002] Except for human donor transplant, attempts at replacing organs or parts of an organ, can be classified into two main approaches, which although sharing some common aspects, are fundamentally different. One is related to Regenerative Medicine and Tissue Engineering and the other is the Artificial or Prosthetic approach. The former relies on cell lineage evolution, selfassembly and reorganization of live primordial cell lines with or without the use of differentiator promoter molecules with the goal to regenerate functional tissue structures (1,2)
[0003] The second, provides largely artificial substitutes, functionally ready to ameliorate or replace the role of an organ (3).
Summary of the Invention
[0004] The aim of this invention is to provide mechanisms for designing prosthetic organ tissue as a scaffold for regenerative organization of organ tissue for organ function supplementation or replacement.
Brief Description of the Figures
[0005] Fig. l is a diagram of a radially disposed, stacked arrangement of a multi-cell prosthetic extracellular matrix (PECM) having centrally located channels.
[0006] Fig. 2 is an electron micrograph of a current commercial stent at 250X magnification illustrating high degrees of surface irregularity and multiple foreign material inclusions with elongated defects along the long axis of the struts.
[0007] Fig. 3 is an illustration of endothelial cells migrating along microscopic, high definition grooves.
[0008] Fig. 4 is an illustration depicting additive physical vapor deposited (PVD) nitinol by orderly nickel and titanium atom deposition from a high energy plasma.
[0009] Figure 5 is an illustration depicting a conceptual prosthetic eye in which electronic output from miniature high-performance cameras elicit image perception when coupled with optic nerve tissue using the PECM of the present invention.
Detailed Description of the Preferred Embodiments
[0010] For purposes of clarity, the following terms used in this patent application will have the following meanings:
[0011] The terminology used herein is for the purpose of describing example embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “'an,” and “the” may be intended to include the plural forms as well, unless the context clearly indicates otherwise. The terms "‘comprises,” "‘comprising,” “including,” and “having,” are inclusive and therefore specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The method steps, processes, and operations described herein are not to be construed as necessarily requiring their performance in the order discussed or illustrated, unless specifically identified as an order of performance. It is also to be understood that additional or alternative steps may be employed.
[0012] When an element or layer is referred to as being “on,” '"engaged,” “connected,” or “coupled” to or with another element, it may be directly on, engaged, connected or coupled to the other element or layer, or intervening elements or layers may be present. In contrast, when an element is referred to as being ‘"directly on,” “directly engaged to,” “directly connected to,” or “directly coupled to” or with another element or layer, there may be no intervening elements or layers present. Other words used to describe the relationship between elements should be interpreted in a like fashion (e g., “between"’ versus "‘directly between,” “adjacent” versus “directly adjacent,” etc.). As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items.
[0013] Although the terms first, second, third, etc. may be used herein to describe various elements, components, regions, layers and/or sections, these elements, components, regions, layers and/or sections should not be limited by these terms. These terms may be only used to distinguish one element, component, region, layer or section from another region, layer or section. Terms such as “first,"’ “second,"’ and other numerical terms when used herein do not imply a sequence or order unless clearly indicated by the context. Thus, a first element, component, region, layer or section discussed below could be termed a second element,
component, region, layer or section without departing from the teachings of the exampie embodiments.
[0014] Spatially relative terms, such as “inner,” “outer,” “beneath,” “below,” “lower,” “above,” “upper," and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. Spatially relative terms may be intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if the device in the figures is turned over, elements described as “below'”, or “beneath” other elements or features would then be oriented “above'" the other elements or features. Thus, the example term “below" can encompass both an orientation of above and below The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly .
[0015] “Substantially” is intended to mean a quantity, property, or value that is present to a great or significant extent and less than, more than or equal to total. For example, “substantially vertical” may be less than, greater than, or equal to completely vertical.
[0016] “About” is intended to mean a quantity, property, or value that is present at ±10%. Throughout this disclosure, the numerical values represent approximate measures or limits to ranges to encompass minor deviations from the given values and embodiments having about the value mentioned as well as those having exactly the value mentioned. Other than in the working examples provided at the end of the detailed description, all numerical values of parameters (e g., of quantities or conditions) in this specification, including the appended claims, are to be understood as being modified in all instances by the term “about” whether or not “about” actually appears before the numerical value. “About” indicates that the stated numerical value allows some slight imprecision (with some approach to exactness in the value; approximately or reasonably close to the value; nearly). If the imprecision provided by “about” is not otherwise understood in the art with this ordinary meaning, then “about” as used herein indicates at least variations that may arise from ordinary methods of measuring and using such parameters. In addition, disclosure of ranges includes disclosure of all values and further divided ranges within the entire range, including endpoints given for the ranges.
[0017] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the recited range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
[0018] References to “embodiment” or “variant”, e.g., “one embodiment,” “an embodiment,” “example embodiment,” “various embodiments,” etc., may indicate that the embodiment s) or variant(s) of the invention so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment,” or “in an exemplary embodiment,” do not necessarily refer to the same embodiment or variant, although they may.
[0019] As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts. Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is in no way intended that an order be inferred, in any respect. This holds for any possible non-express basis for interpretation, including matters of logic with respect to arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
[0020] The term “material” is intended to refer to elemental metals, alloyed metals or pseudometals.
[0021] For purposes of this application, the terms “pseudometal” and “pseudometallic” are intended to mean materials which exhibit material characteristics substantially the same as metals. Examples of pseudometallic materials include, without limitation, composite materials, polymers, and ceramics. Composite materials are composed of a matrix material reinforced with any of a variety of fibers made from ceramics, metals, carbon, or polymers.
[0022] As used in this application the term “layer” is intended to mean a substantially uniform material limited by interfaces between it and adjacent other layers, substrate, or environment. The interface region between adjacent layers is an inhomogeneous region in which extensive thermodynamic parameters may change. Different layers are not necessarily characterized by different values of the extensive thermodynamic parameters but at the interface, there is a local change at least in some parameters. For example, the interface between two steel layers that are identical in composition and microstructure may be characterized by a high local concentration of grain boundaries due to an interruption of the fdm growth process. Thus, the interface between layers is not necessarily different in chemical composition if it is different in structure.
[0023] The term “build axis” or “build direction” is intended to refer to the deposition axis in the material. For example, as a material is being deposited onto a substrate, the thickness or Z-axis of the material being deposited will increase, this is the build axis of the material.
[0024] The terms “circumferential” or “circumferential axis” is intended to refer to the radial direction of a tubular, cylindrical or annular material or to the Y-axis of a polygonal material.
[0025] The terms “longitudinal,” “longitudinal axis,” or “tube axis” are intended to refer to an elongate aspect or axis of a material or to the X-axis of the material.
[0026] The term “bulk material” is intended to refer to the entirety of the material between its surfaces.
[0027] The term “film” is intended to encompass both thick and thin films and includes material layers, coatings and/or discrete materials regardless of the geometric configuration of the material.
[0028] The term “thick film” is intended to mean a film or a layer of a film having a thickness greater than 10 micrometers.
[0029] The term “thin film” is intended to mean a film or a layer of a film having a thickness less than or equal to 10 micrometers.
[0030] The terms “physical vapor deposition” and/or is acronym “PVD” is intended to encompass the processes of sputtering, electron-beam deposition, hot-boat evaporation, reactive evaporation, ion platting, plasma sputtering and/or ion beam sputtering.
[0031] It may be argued that artificial replacements have had a broader impact in medicine, in part due to their longer history of development and because they have readily benefited from the latest technological advances in materials science, fabrication and microelectronics. Implantable devices are currently common tools of practice in several medical specialties: Ocular lens implants have been time-proven in ocular surgery (4) and cochlear implants are becoming increasingly sophisticated (5). Cardiac pacemakers and ICD (implantable cardioverter defibrillator), are probably the most successful standalone microelectronic implants so far (6). In orthopedic surgery, rehabilitation of knee function due to osteochondral degenerative changes currently uses both approaches: intra capsular introduction of cartilage building promoters (7) and total artificial joint replacement (8). Given the importance of life-style changes in patients with knee joint disease and the need to quickly restore them to deambulation, the prosthetic approach has been the most widely adopted. Other prosthetic joint substitutes like the artificial hip joint, have reached state-of-the art status, with high safety and efficacy (9). Osteo-integrated dental implants have significantly advanced prosthetic dentistry (10
[0032] Implantable cardiovascular prosthetics have been very effective and enjoy a long history of successful development: Surgical and transluminal vascular grafts and stent grafts and prosthetic cardiac valves (11), caval filters (12) coronary stents (13,14) , patent foramen ovale occluders (15), atrial appendage closure devices (16) mitral valve repair clip (17), transluminal aortic valve replacement (18) among many others, already available or in development.
[0033] Regenerative strategies have been attempted in the cardiovascular system, but they have not been quite as successful as prosthetic devices. Cardiac muscle regeneration was attempted with intracoronary infusion of myoblasts (19). Also, cardiac muscle injection of progenitor cells was evaluated in patients as a therapy for no-option angina (20). The improvements achieved with these approaches have been modest at best and inconclusive insofar the claimed mechanism of action (21). Myocardial revascularization with gene therapy promoting angiogenesis (22) or implantation of endothelial progenitor cells (EPG’s) has yielded modest or controversial results (23).
[0034] Bioresorbable vascular stents (BRS) can be considered a regenerative approach insofar as the theory upon which they are based. Founded on the assumption that the diseased vascular wall tissues would reorganize into functional structures, vasomotion and positive remodeling was expected concurrently with the disappearance of the scaffold (24). Although the BRS proved equivalent to drug eluting metal stents in pivotal randomization trials (25) they have been clinically abandoned as post-approval clinical evidence cast doubts about their safety and efficacy (26). Some late thrombotic events with the BRS coincided in time with complete scaffold reabsorption supporting the notion that a permanent stent scaffold may be needed to replace the loss of the arterial connective structure. This is an important component of atherosclerotic vascular occlusive disease as the vessel structure supports endothelial cell function and stability (27).
Progenitor stem cells as the building blocks for regenerative therapies of solid organs. [0035] Progenitor stem cells (PSC) from fetal tissues, umbilical cord, bone marrow, or fibroblast cell lines (28) can be induced to produce mature lineage cells as neural, hepatic, cardiac, renal and so forth (29). This brought about a large and ongoing body of research based on the possibility of regeneration of organs for in vitro or in vivo applications (30).
[0036] At present, the creation of fully functional isolated organs from progenitor cells appears rather remote from current perspective (31,32), but substantial work is being done with infusion of progenitor cells in diseased organs aiming at replacing cellular loss. While there are currently more than twelve hundred mesenchymal stem cell (MSC) clinical trials (Clinical trials.gov) large scale, controlled clinical studies have often failed to substantiate the benefit suggested by smaller trials (33).
[0037] The co-location of constituent cells in the correct position and arrangement in an artificial or biological matrix has been attempted by recellularization of decellularized organs like lungs (34) and cardiac valves (35). Work with 3D printing of cells and viscoelastic matrices is progressing through preliminary stages (36). The use of porous hydrogels or bioresorbable materials such as polyglycolic acid as tissue scaffolds rely on the expectation that progenitor cells will home, assemble, differentiate and promote the formation of their own support infrastructure including vascular supply and lymphatic/venous drainage among other tissue
architectural features. Based on currently available experimental evidence, it seems that the expectation of spontaneous generation of tissue infrastructure may be over optimistic.
[0038] Engineered prosthetic cellular scaffolds may be more realistic tissue platforms as conceptualized by constructs such as suggested in Figs. 1A-1C. Figure 1A and IB illustrates a radially disposed, stacked arrangement of a multicellular prosthetic extra cellular matrix (PECM) 10 in accordance with the present invention. The PECM includes individual modules 12 interconnected along their Z-axis by centrally located channels 14 that extend along a longitudinal axis of the PECM 10 for vascular supply to and drainage from the cells for a plurality of compartments 16 on each individual PECM module 12. Each individual module 12 may be formed as a coherent fdm and then assembled as a multi-layer structure of coherent films or, alternatively, as a layer in a multi-layer film of biomaterial. Cellular guidance and location may be facilitated by microgrooved channels 18 extending between the centrally located channels 14 and the plurality of compartments 16. Fluids, solutes, and molecular exchange is promoted by the centrally located Z-axis channels 14 extending between the stacked PECM modules 12. Fig. IB illustrates the Z-axis stacked array of the individual modules 12 forming the PECM.
[0039] Fig. 1C illustrates an individual compartment 16, with a plurality of microgrooved channels 18 communicating between other compartments 18 the plurality of compartments. Also shown in Fig. 1C are cells 19 that are either seeded onto the compartments 18 or migrated to a compartment.
[0040] It will be understood that alternative architectures of PECM arrangements are both intended and contemplated by the present invention other than the specific example illustrated in Figs. 1A-1C, including, for example compartmentalized multi-cellular structures in which the compartments are capable of communicating fluids, solutes, and molecular exchange between compartments.
[0041] Prosthetic scaffolds may be more plausible as engineered extracellular matrices may guide cell growth, location and differentiation to achieve the goal of functional semisynthetic organs. Progenitor cell seeding into or onto the extracellular matrix of the prosthetic scaffold may further be performed to enhance populating of the extracellular matrix. As these fledging efforts progress through basic science proof of concept to eventual practical reality, it is not inconceivable that future replacement organs will be bioprosthetic constructs rather than all-
biological laboratory organs ready to be surgically implanted like donor allografts. Practically speaking, prosthetic constructs have logistical advantages compared to biological constructs insofar control of measurable parameters, fabrication techniques and reproducibility. Controlled progression to increasing complexity is another advantage of prosthetics and may translate into more predictable and consistent results.
Organ transplantation:
[0042] Organ transplantation of live or decellularized tissue may not be considered regenerative therapy since the transplanted organ or parts of an organ, whether it be a homograft, allograft or xenograft is functionally developed and aims at readily substitute a diminished or absent function. Optimally, live donor transplant is well tolerated by the recipient provided MHC, HLA, ABO compatibility, adjuvant chemotherapy and prevention of infection and other potentially adverse events (37). Although not a solid organ, allogenic or autologous transplants of blood precursors in the bone marrow routinely restore blood cell production in patients with bone marrow depletion by chemo or radiation therapy. However, blood producing bone marrow cells are among human tissues of rapid growth that provide for the attrition of their end-of-the-line constituents and, their spontaneous differentiation is actually pre-determined, not manipulated and, or induced. Same applies to skin and biological cardiac valves. Corneal transplants, ligaments, bone and cartilage grafts should be considered developed tissues with full functional capability like the lung, pancreas, kidney, liver and heart. Therefore, they fall outside of the frame that define regenerative therapies.
From scaffolds to prosthetic extracellular matrix (PECM)
[0043] To create tissue scaffolds whose function would approximate the biological extracellular matrix (ECM) paradigm changes in understanding, design and fabrication methods must be made. In regard to structures build with prosthetic biomaterials, most work has been within the macroscopic or microscopic realm. Technologies such as fabrication methods, biomechanical performance and quality assurance apply largely to the visible size range with or without the assistance of optical magnification. The optimal range of most technologies used in the medical device industry is at the sub-millimeter and micron level as defined by industrial manufacturing
tolerances. This may be adequate for current device technology but insufficient for sub-micron and nanometer detail.
[0044] While pharmacological agents are designed focusing on molecular interactions with cell membrane receptors and other nanoscopic size targets, implantable biomaterials interaction with biological tissues are usually assessed by histopathological effects such as mechanical injury and surface boundary phenomena such as thrombogenicity and inflammation. The focus should shift from the micron to the nanometer world for the assessment of material interactions with living tissues.
[0045] It is known, for example, that current commercial biomaterials, such as those used to fabricated vascular stents, have high degrees of surface irregularities at the microscopic level and multiple foreign material inclusions, such as carbide inclusions or residual from process lubricants. Figure 2 is an electron micrograph illustrating such features in a commercially available vascular stent. It has been demonstrated that such surface irregularities and foreign material inclusions are impede or even prevent cellular attachment and proliferation on the material surfaces resulting in either incomplete or non-incorporation of the devices into the biological tissue. As such, current materials are sub-optimal as prosthetic tissue scaffolds, particular for organ tissue regeneration.
[0046] As progress is made into a smaller dimensional world, each step down creates new challenges. This is already evident in the quality assurance and lower tolerance levels of implantable microdevices, requiring increasingly sophisticated measuring equipment and computer data management to cope with the ever increasing design complexity and volume of QA data.
[0047] The commitment to design and manufacture at the nano-scale is neither simple nor economically efficient in the present reality of the medical device industry. However, efforts must be undertaken to change current simplistic approaches to new devices. This is not easy because approved devices are currently considered safe and effective by older stablished criteria. However, adherence to these criteria is a hinderance to progression to more sophisticated devices and even unforeseen new applications.
A peek into cellular response to engineered surfaces
[0048] Controlled nanofabrication on artificial surfaces allows for micro-engineering of prosthetic surfaces in a manner that is highly controllable. Working on micro-engineering of the surface of implantable vascular stents materials new techniques for fabrication of high definition microgrooves have been developed. The goal was to increase the migration speed and influence growth direction of human aortic endothelial cells to accelerate colonization and therefore positively influence the prosthetic healing process. Engineered micro-grooves have been made that are within the size range of vascular endothelial cells (EC). An effort was made to maintain the features definition within few hundred nanometers. As technology moved from abrasive to laser, to photolithography manufacturing techniques it was quickly realized that the limiting factor was the materials being working with. The engineered features on the prosthetic surface that were initially used were within the size range of currently accepted surface topography variability. This implied that to fabricate those features with consistent regularity the putative background surface had to be chemically and topographically more uniform. The result of trying many iterations of fabrication techniques and material, revealed the importance of the edge definition of the features. In other words, the cellular response increased with control of feature regularity at submicroscopic level. Migrating endothelial cells are sensitive to surface topography whether this is by their physical presence or by redistribution of surface adhesive proteins. Un-interrupted outer edges and inner corners act as guides for the EC lamellipodia and other migrating cell filopodia to follow, pulling the rest of the cell behind.
[0049] Figure 3 depicts a portion of a biomaterial, for example, a biomaterial that makes up a portion of the PECM modules 12 of the inventive organ tissue scaffold 10. Endothelial or other cells 24 directionally migrate along the microscopic, high-definition grooves 22 in surfaces of the biomaterial. In this manner, cells 24 can proliferate and migrate along the grooves 22 to populate the compartments 16 of each module 10 in the PECM tissue scaffold 10. The grooves directional guide the proliferation and migration of the cells, increasing their translation speed and their ability to more rapidly colonize a surface of the PECM biomaterial and compartments 16.
[0050] This guidance effect is lost as the feature edge gets interrupted. Thereby, the importance of high-definition longitudinal feature continuity. Guidance effects can be an approach to correctly locate cells within a matrix whether they be endothelial, epithelial, parenchymal or osteoblastic cellular arrays, or attempts at neuroaxonal reconnection. This pursuit necessitates the
development of new biomaterials to allow fabrication in the sub-microscopic range. By achieving nanoscopic controlled features a surprising and unexpected change in cellular response from random to consistent was observed. Higher quality levels of material composition defined as topographical and chemical homogeneity and enhanced robustness provide an adequate canvass for new, high-definition designs and fabrication. Currently, the metal alloys used for most implantable devices have marked crystal size variability and carry lattice defects and impurities in the form of inclusions from fabrication residues (39). These materials cannot be used to make device features with sub-microscopic detail. This is also important with device features smaller than the size of a single crystal or inclusion deposit in current bio-alloys as corrosion and fatigue resistance quickly diminish with miniaturization.
[0051] As prosthetic scaffolds evolve toward microscopic designs, the architecture of the PECM to favor cell attachment mechanisms, fluids exchange, large and small molecular movement, immune cell migration and apoptotic cell debris disposal (Figure 1, PECM construct) must be addressed and considered. With the development of microscopic intricate designs, the materialcell surface interface will increase exponentially to the point that physical chemistry properties of the material will become critical. Probably, current levels of acceptance to ion release, surface hydropathy, electrical charge, stability of surface oxides and other surface properties will become central as they determine selective adhesive protein distribution and interaction with surfaces. Like with current designs, resistance to corrosion, elasticity, strength and fatigue limits, will be dependent on each application. But, given the intricacy and complexity of future designs, assessment of biomechanical parameters will become more difficult. Nonetheless, these complex constructs may be surprisingly robust as prosthetic/living tissue association may introduce new aspects of composite materials engineering, previously ignored or underestimated.
A new manufacturing environment
[0052] Current devices are largely made by top-down or reductive manufacturing. These classical technologies rely on extensive and skilled hand labor, produce waste and suffer from relatively large product variability and rejection rates. Reductive manufacturing commonly involves a complicated series of steps, each one leaving footprints that affect the surface chemical and topographical homogeneity. As complex microscopic and submicroscopic constructs are considered, these methods may no longer be useful. Human manual processing
will be replaced by automated manufacturing and new technologies uncommon in the medical device industry today will be common place. This is the case for physical vapor deposition (PVD) of metals and alloys, ceramics and polymers and extensive robotic use of photolithography and femto-second lasers.
[0053] Additive PVD achieves an orderly deposition of metal or pseudometal atoms from a high energy plasma. Figure 4 is an illustration at of this orderly deposition of nitinol from nickel and titanium atoms. PVD process are highly controllable to yield predictive material properties in the resulting deposited material. Moreover, the structures of the deposited materials may have complex geometries based upon the geometry of the substrate onto which the deposition occurs. Thus, the cellular scaffold elements of the inventive PECM may be formed by PVD processes by vacuum depositing the desired metal or pseudometal onto substrates having geometries corresponding to the desired shape of the cellular scaffold elements. It will be understood, of course, that other metals or pseudometals may be vacuum deposited, such as cobalt-chromium alloys, stainless steel, ternary or quaternary alloys, or the like.
[0054] The enabling technologies are today more ubiquitous in energy and electronics fields than in medical devices. Most importantly, quality assurance and control requirements will exponentially increase with complex, smaller devices, requiring larger computer data processing. The use of machine learning and artificial intelligence (Al) will allow for an increase in the role of high-power computers in all aspects of new devices from complex designs, to manufacturing, to quality control and data handling. The new manufacturing facilities will likely have smaller physical plants, fewer operators and substantial computer involvement.
[0055] The evolution of technology toward fabricating features dimensionally closer to the size of cells is inevitable but the technology will change to the point it does no longer resemble what is a typical medical device company. The regulatory agencies may need to adapt to the change by shifting the emphasis from device-centered to method-centered, thereby regulating the certification of processes that allow for flexibly changing design and eventually facilitating personalized device manufacturing.
[0056] In some ways, future creation of new devices will resemble new drug design and manufacturing that focus on subcellular targets. Surface chemistry at device surfaces as well as surface topography at the molecular level and its effect on and interaction with cells and molecules must be conside4red. This calls for a fundamental change in the way prosthetic
constructs and design will address the molecular make-up of the biological environment rather than using the current adaptive/adoptive approach. In other words, no longer available materials and technologies will be borrowed from other fields, based on their procure-ability, practicality and implementation by trial and error. Rather, materials and methods will be tailor-made to fit applications.
[0057] Eventually, fabrication of devices will be chemical -based. Partly in-vitro and partly in- vivo, the assembly of microscopic components will be managed by complementary reactants strategically placed in nanoblocks with geometrical growth capability. Architectural plasticity will be managed by computer control of reactants acting as chemical triggers of hierarchical in- vivo growth. Carbon nanoparticles maybe possible candidates for their material properties and the -ability for chemical derivatization. However fascinating, chemical based in-vivo prosthetic build-up is farther in the future that the possibilities presently at hand. (40).
[0058] What will be the next big step in the discovery and application of organ replacements is hard to predict as so many factors influence these evolutionary trends. However, some pieces of this puzzle are already in place providing a glimpse of what may be the next big thing in this area. Starting with prosthetic biomaterials, the use of Al to create super-materials may eliminate what is today a long and tedious process to arrive at products with ideal properties by trial and error. Computers will tell us the ideal combination of components with perfect stoichiometry for optimized properties for a given application (41). Superalloys will be made overnight in vacuum plasma reactors rather than in foundry furnaces. Manufacturing labor, waste and rejection of out of specification product will be almost eliminated.
[0059] Progress in understanding tissue transmission of electrical and electromagnetic energy (42) is already influencing implantable technologies like cardiac pacing, in the application of addressable lead-less pacemakers (43). Also, it should aid in new developments in neuroscience technology to successfully establish connectivity between electrical impulses originated in the brain and external actuators, or from impulses generated extracorporeally to elicit specific neuronal excitation (44). This will open up long-awaited opportunities for rehabilitating victims of traumatic and degenerative brain-spinal disfunction resulting in enabled motor function and speech. It is not hard to imagine that if brain connectivity is finally conquered, vision and auditory functions can also be restored. Furthermore, with current available technologies is easy to imagine enhanced sensory functions as high definition, infrared and ultra-low light vision.
[0060] Figure 5 illustrates a conceptual depiction of a prosthetic eye that employs high- performance camera(s) as part of the eye prosthesis. The electrical output from the cameras must communicate with the optical neural pathways. Such communication is made possible by constructing a multi-cellular PECM of the present invention, seeding or growing nerve cells as an optical neural pathway onto the PECM to conduct electrical signals from the camera(s) of the prosthetic eye to the optic nerve or other neural pathway to the brain.
[0061] This same principle applies to all sensory organs, such as enhancing or replacing pathways for touch, taste, smell, hearing or the like. Following this line of thought is also conceivable that radio communications allowed by an effective computer brain-interface will provide access of just about all the telecommunications and internet connectivity that most human beings presently enjoy by mere conscious thinking.
The social impact of prosthetic replacements
[0062] The improvement in quality of life that many prosthetic devices offer to the aging population are amazing. This is mainly by alleviating life-style limiting conditions that were previously ostracizing and, or debilitating and contributed to the inevitable decline of old age. [0063] However, more significant is the progressive disappearance of the prosthetic stigma. The ancient prototypical wooden leg, ear horn and the gold tooth have given place to high tech limb prosthesis and imperceptible tooth implants. Just as important as the functional benefit they provide, is the decrease of real or perceived social isolation imposed by the need of using odd prosthetic replacements or aids. It can easily be imagine that if enhanced vision and other sensory functions become available, the level of acceptance will be even higher or even be replaced by a sense of pride in the user. Electro-mechanically assisted exo-skeletal frames are commonplace in assembly lines to assist high effort operations (45). It is not inconceivable that they will replace the traditional wheel-chair, particularly if they can be operated by volitive brain command.
[0064] In other words, the lines between handicapped and non-handicapped people may start blurring out and many of these life-facilitating and life-enhancing prosthetic assists may have profound influences in society.
References
1. Meritxell Huch, Juergen A. Knoblich, Matthias P. Lutolf, Alfonso Martinez- Arias The hope and the hype of organoid research Development 2017 144: 938-941
2. G Rossi, A Manfrin, M Lutolf. Progress and potential in organoid research. Nature Reviews Genetics 19, 671-687;2018
3. B Ratner, A Hoffman, F Schoen, J Lemons. Biomaterials Science 2nd ed. Elsevier Academic Press, 2004
4. D Allen, A Vasavada. Cataract and surgery for cataract. BMJ 2006, 333: 128-132
5. Lenarz. Chloclear implant-state of the art. GMS Curr Top Otorhinolarygol Head Neck Surg 2017;16:Doc
6. Trohman R, Kim M, Pinski S. Cardiac pacing: State of the art. The Lancet 2004;364(9446): 1701-19
7. K Filardo, G Roffi, A Andriolo, L Marcacci M. New trends for knee cartilage regeneration: From cell-free scaffolds to mesenchymal stem cells. Curr Rev Musculoskelet Med 2012; 5:236
8. J Feng, D Novikov, A Anoushiravani, Ran Schwarzkopf. Total knee arthroplasty: Improving outcomes with a multidisciplinary approach. J Multi di scip Health 2018;! 1 :63
9. U Holzwarth, G Cotogno. https://ec.europa.eu/jrc/en/publication/eur-scientific-and- technical-research-reports/total-hip-arthroplasty-state-art-prospects-and-challenges).
10. D Hong, J Oh. Recent advances in dental implants. Maxillofac Plast Reconstr Surg 2017;39(l):33
11. F Johnson, K Virgo. The bionic human. Humana press inc. 2006. NJ 07512. Chapter 18, p 641
12. E De Young, J Minocha. Inferior vena cava filters: Guidelines, best practice and expanding indications. Sem Intervent Radiol 2016;33 (2):65-70
13. R Schatz, Goldberg S, M Leon, et al. Clinical experience with the Palmaz- Schatz stent. JACC 1991 1991;17(6):155B-9B. D Fischman, D Bairn, R Schatz, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. NEJM1994;331 :496-501.
14. P Serruys, P de Jaegere, F Kiemeeneij, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.
NEJM1994;331 :489-495
15. F Collado, M Poulin, J Murphy et al. Patent foramen ovale closure for stroke prevention and other disorders. J AHA 2018;7e007 146. DOI: 10.1161/JAHA.l 17.007146
16. G Casu, G Gulizia, G Molon, et al. ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients:indications, patient selection, staff skills, organization and training. European Heart Journal Suppl 2017. 19 (suppl D), D333-D353
17. N Oh, P Kampaktsis, M Gallo, et al. An updated meta-analysis of MitraClip versus surgery for mitral regurgitation. Ann Cardiothorac Surg 2021 ; 10(1): 1-14
18. V Kumar, G Sanhdu, C Harper et al. Transcatheter aortic valve replacement programs: Clinical outcomes and developments. J Am Heart
Assoc.2020:e015921. DOI: 10.1161/JAHA.120.015921
19. K Suzuki, B Murtuza N Suzuki, R Smolenski, M Yacoub. Intracoronary infusion of skeletal myoblasts improves cardiac function in Doxorubicin-induced heart failure Circulation 2001;104(I):I-213-217
20. T Henry, Losordo D, J Traverse, R Schatz, et al. Autologous CD34 cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. European Heart J 2018;39:2208-2216
21. L He, N Nguyen, R Ardehali, B Zhou. Heart Regeneration by endogenous stem cells and cardiomyocyte proliferation. Controversy, fallacy and progress. Circulation 2020;142:275-291).
(M Seidel M,A Borczynska, N Rozwadowska, M Kurpisz. Cell-based therapyfor heart failure: Skeletal myoblasts. Cell Transplantation 2009; 18:695-707
22. S Yla-Herttuala, C Bridges, M Katz, P Korpisalo. Angiogenic gene therapy in cardiovascular diseases: dream or vision? European Heart Journal 2017;38:1365-1371
23. S Aurangzeb, E Shantzila, G Lip, C Varma. Endothelial progenitor cells: What use for the cardiologist? J Angiogenesis Res 2010; 2(1):6). (J Pearson.Endothelial Progenitor cells-hype or hope? J Thromb Haemost, 2009;7:255-62
24. J Lane, L Perkins, A Sheehy, et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries. JACC: Cardiovascular Interventions 2014;7(6):688-695
25. G Stone, R Gao, T Kimura, et al. 1 year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet 2016;387: 1277-89
26. D Kereiakes, S Ellis, C Metzger, et al. 3-year outcomes with everolimus-eluting bioresorbable coronary scaffolds. The absorb III trial. JACC 2017;70(23):2852-62
27. S Dhawan, R Nanjundappa, J Branch, R Taylor, et al. Shear stress and plaque development. Expert Rev Cardiovasc Ther. 2010;8(4): 545-556
28. T Ichim, P O’Heeron, S Kesan. Fibroblasts as a practical alternative to mesenchymal stem cells. J Transl Med 2018;16:212
29. E Yang, N Liu, Y Tang et al. Generation of Neurospheres from human adipose-derived stem cells. Biomed Res. Int. 2015;2015:743714
30. T Chen, F Wang, M Wu, Z Wang. Development of hematopoietic stem and progenitor cells from human pluripotent stem cells. J Cell Biochem 2015; 116(7): 1179-89
31. Meritxell Huch, Juergen A. Knoblich, Matthias P. Lutolf, Alfonso Martinez- Arias. The hope and the hype of organoid research Development 2017 144: 938-941
32. G Rossi, A Manfrin, M Lutolf. Progress and potential in organoid research. Nature Reviews Genetics 19, 671-687;2018
33. S Ezquerra, A Zuleta, R Arancibia, et al. Functional properties of human-derived mesenchymal stem cells spheroids: A meta-analysis and systemic review. Stem Cells Int 2021 :8825332), (J Galipeau, L Sensebe. Mesenchymal stromal cells:clinical challenges and therapeutic opportunities. Cell Stem Cell 2018;l :22(6):824-833
34. T Tsuchiya, A A Sivarapatna, K Rocco, et al. Future prospects for tissue engineered lung transplantation. Organogenesis 2014; 10(2): 196-207
35. A Bonetti, M Marchini, F Ortolani. Ectopic mineralization in heart valves: New insights from in-vivo procalcific models and promising perspectives on non-calcifiable bioengineered valves. J Thorac Dis 2019;l l(5):2126-2143
36. M Skylar-Scott, S Uzel, L Nam, et al. Biomanufacturing of organ specific tissues with high cellular density and embedded vascular channels. Sci Adv. 2019;5:eaaw2459
37. M Ayala Garcia, B Yebra, A Lopez florez, E Guerra. The Major Histocompatibility Complex in transplantation. Journal of Transplantation 2012. Article ID 842141
38. E Sprague, F Tio, H Ahmed, et al. Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation and function. Circulation Cardiovascular Interventions 2012;5(4):499-507
39. P Adler R Frei, M Kimiecik. Effects of tube processing on the fatigue life of nitinol. Shap. Mem. Supeerelasticity (2018) 4:197-217
40. J Palmaz https://www.youtube.com/watch?v=W7JxWUoKL8
41. G Ceder, K Persson. 2013 https://www.scientificamerican.com/article/how- supercomputers-will-yield-a-golden-age-of-materials-science/
42. JA Tuszynski. 2018 https://www.ncbi.nlm.nih.gov/books/NBK549549/
43. F Tjong, V Reddy. Permanent leadless cardiac pacemaker therapy. Circulation 2017;135(15): 1458-7
44. S Begley. 2018 https://www.scientificamerican.com/article/with-brain-implants- scientists-aim-to-translate-thoughts-into-speech/
45. S Fox,O Aranko, J Heilala, P Vahala. Exoskeletons: Comprehensive, comparative and critical analysis of their potential to improve manufacturing performance. J Manufacturing Technology Management 2019;31 (6): 1261 -8
Claims
1. A method of making a regenerative organ tissue scaffold, comprising the steps of forming at least two of a plurality of compartments; assembling the at least two of a plurality of compartments into a three-dimensional array; and forming a plurality of channels communicating a Z-axis of the three-dimensional array configured for vascular supply and/or drainage from each of the plurality of compartments in the three-dimensional array.
2. The method of Claim 2, wherein each of the plurality of compartments are configured to be in physiological and/or biological communication with each other along at least two axes of the three-dimensional array.
3. The method of Claim 2, wherein the step of forming at least two of a plurality of compartments further comprises additive physical vapor depositing the at least two of a plurality of compartments.
4. The method of Claim 4, wherein the additive physical vapor depositing further comprises the step of physical vapor depositing a first compartment onto a substrate followed by the step of physical vapor depositing a second compartment on the substrate.
5. The method of Claim 5, further comprising the step of forming a plurality of grooves on surfaces of each of the plurality of compartments.
6. The method of Claim 6, further comprising the step of configuring the plurality of grooves to provide cellular pathways for cells to colonize surfaces of the plurality of compartments.
7. The method of Claim 7, wherein the plurality of grooves are configured to have submicron size widths and depths.
8. The method of Claim 1, wherein the step of forming at least two of a plurality of compartments further comprises the step of configuring the at least two of a plurality of compartments in a radially disposed and stacked arrangement to form a multicellular prosthetic extra cellular matrix.
9. The method of Claim 9, wherein the plurality of channels are configured to communicate between each of the plurality of compartments.
10. The method of Claim 1 , wherein the step of forming at least two of a plurality of compartments further comprises the step of physical vapor depositing at least one metal, pseudometal, alloy, ceramic, composite, or polymer.
11. The method of Claim 11, wherein the step of physical vapor depositing further comprises the step of depositing a nickel -titanium alloy.
12. The method of Claim 1, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises the step of sputtering.
13. The method of Claim 1, further comprising the step of seeding progenitor cells onto the at least two of a plurality of compartments.
14. The method of Claim 1, further comprising the step of seeding progenitor cells onto multicellular prosthetic extra cellular matrix.
15. The method of Claim 14, wherein the progenitor cells are selected from endothelial progenitor cells, progenitor stem cells and/or bone marrow cells.
16. The method of Claim 15, wherein the progenitor cells are selected from endothelial progenitor cells, progenitor stem cells and/or bone marrow cells.
17. A method of making a regenerative organ tissue scaffold, comprising the steps of physical vapor depositing at least one metal, pseudometal, alloy, ceramic, composite, or polymer. to form a plurality of compartments; assembling the plurality of compartments into a three-dimensional array comprising a radially disposed and stacked arrangement of the plurality of compartments configured to form a multicellular prosthetic extra cellular matrix; configuring the plurality of compartments to be in physiological and/or biological communication with each other along at least two axes of the three- dimensional array; and forming a plurality of channels communicating a Z-axis of the three-dimensional array configured for vascular supply and/or drainage from each of the plurality of compartments in the three-dimensional array.
18. The method of Claim 18, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises additive physical vapor depositing the at least two of a plurality of compartments.
19. The method of Claim 19, wherein the additive physical vapor depositing further comprises the step of physical vapor depositing a first compartment onto a substrate followed by the step of physical vapor depositing a second compartment on the substrate.
20. The method of Claim 20, further comprising the step of forming a plurality of grooves on surfaces of each of the plurality of compartments.
21. A regenerative organ tissue scaffold, comprising a plurality of compartments organized in a three-dimensional array, each of the plurality of compartments being in physiological and/or biological communication with each other along at least two axes of the three- dimensional array; and a plurality of channels communicating along a Z-axis of the three- dimensional array configured for vascular supply and/or drainage from each of the plurality of compartments in the three-dimensional array.
22. The regenerative organ tissue scaffold of Claim 21, wherein each of the plurality of compartments are configured to be in physiological and/or biological communication with each other along at least two axes of the three-dimensional array.
23. The regenerative organ tissue scaffold of Claim 21, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises additive physical vapor depositing the at least two of a plurality of compartments.
24. The regenerative organ tissue scaffold of Claim 24, wherein the additive physical vapor depositing further comprises the step of physical vapor depositing a first compartment onto a substrate followed by the step of physical vapor depositing a second compartment on the substrate.
25. The regenerative organ tissue scaffold of Claim 24, further comprising the step of forming a plurality of grooves on surfaces of each of the plurality of compartments.
26. The regenerative organ tissue scaffold of Claim 25, further comprising the step of configuring the plurality of grooves to provide cellular pathways for cells to colonize surfaces of the plurality of compartments.
27. The regenerative organ tissue scaffold of Claim 26, wherein the plurality of grooves are configured to have sub-micron size widths and depths.
28. The regenerative organ tissue scaffold of Claim 21, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises the step of configuring the at least two of a plurality of compartments in a radially disposed and stacked arrangement to form a multicellular prosthetic extra cellular matrix.
29. The regenerative organ tissue scaffold of Claim 28, wherein the plurality of channels are configured to communicate between each of the plurality of compartments.
30. The regenerative organ tissue scaffold of Claim 29, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises the step of physical vapor depositing at least one metal, pseudometal, alloy, ceramic, composite, or polymer.
31. The regenerative organ tissue scaffold of Claim 30, wherein the step of physical vapor depositing further comprises the step of depositing a nickel -titanium alloy.
32. The regenerative organ tissue scaffold of Claim 21, wherein the step of physical vapor depositing at least two of a plurality of compartments further comprises the step of sputtering.
33. The regenerative organ tissue scaffold of Claim 21, further comprising the step of seeding progenitor cells onto the at least two of a plurality of compartments.
34. The regenerative organ tissue scaffold of Claim 21, further comprising the step of seeding progenitor cells onto multicellular prosthetic extra cellular matrix.
35. The regenerative organ tissue scaffold of Claim 34, wherein the progenitor cells are selected from endothelial progenitor cells, progenitor stem cells and/or bone marrow cells.
36. The regenerative organ tissue scaffold of Claim 35, wherein the progenitor cells are selected from endothelial progenitor cells, progenitor stem cells and/or bone marrow cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/752,813 US20220370185A1 (en) | 2021-05-24 | 2022-05-24 | Scaffold for Regenerative Organization of Prosthetic Organ Tissue and Method |
US17/752,813 | 2022-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023230535A1 true WO2023230535A1 (en) | 2023-11-30 |
Family
ID=87695917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/067435 WO2023230535A1 (en) | 2022-05-24 | 2023-05-24 | Scaffold for regenerative organization of prosthetic organ tissue and method |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023230535A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036357A2 (en) * | 2006-09-20 | 2008-03-27 | Boston Scientific Scimed, Inc. | Medical devices having biodegradable polymeric regions with overlying hard, thin layers |
WO2014207462A1 (en) * | 2013-06-27 | 2014-12-31 | The University Of Warwick | Biomedical scaffold |
WO2017050837A1 (en) * | 2015-09-23 | 2017-03-30 | Novus Scientific Ab | Three-dimensional medical implant for regeneration of soft tissue |
WO2019104392A1 (en) * | 2017-11-30 | 2019-06-06 | Queensland University Of Technology | Modular tissue implants |
US20220008621A1 (en) * | 2020-07-09 | 2022-01-13 | Industry Foundation Of Chonnam National University | Plasma-assisted flexible multi-scale topographic patches for engineering cellular behavior and tissue regenration |
-
2023
- 2023-05-24 WO PCT/US2023/067435 patent/WO2023230535A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036357A2 (en) * | 2006-09-20 | 2008-03-27 | Boston Scientific Scimed, Inc. | Medical devices having biodegradable polymeric regions with overlying hard, thin layers |
WO2014207462A1 (en) * | 2013-06-27 | 2014-12-31 | The University Of Warwick | Biomedical scaffold |
WO2017050837A1 (en) * | 2015-09-23 | 2017-03-30 | Novus Scientific Ab | Three-dimensional medical implant for regeneration of soft tissue |
WO2019104392A1 (en) * | 2017-11-30 | 2019-06-06 | Queensland University Of Technology | Modular tissue implants |
US20220008621A1 (en) * | 2020-07-09 | 2022-01-13 | Industry Foundation Of Chonnam National University | Plasma-assisted flexible multi-scale topographic patches for engineering cellular behavior and tissue regenration |
Non-Patent Citations (41)
Title |
---|
A BONETTIM MARCHINIF ORTOLANI: "Ectopic mineralization in heart valves: New insights from in-vivo procalcific models and promising perspectives on non-calcifiable bioengineered valves", J THORAC DIS, vol. 11, no. 5, 2019, pages 2126 - 2143 |
D ALLENA VASAVADA: "Cataract and surgery for cataract", BMJ, vol. 333, 2006, pages 128 - 132 |
D FISCHMAND BAIRNR SCHATZ ET AL.: "A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease", NEJM, vol. 331, 1994, pages 496 - 501 |
D HONGJ OH: "Recent advances in dental implants", MAXILLOFAC PLAST RECONSTR SURG, vol. 39, no. 1, 2017, pages 33 |
D KEREIAKESS ELLISC METZGER ET AL.: "3-year outcomes with everolimus-eluting bioresorbable coronary scaffolds", THE ABSORB III TRIAL. JACC, vol. 70, no. 23, 2017, pages 2852 - 62 |
E DE YOUNGJ MINOCHA: "Inferior vena cava filters: Guidelines, best practice and expanding indications", SEM INTERVENT RADIOL, vol. 33, no. 2, 2016, pages 65 - 70 |
E SPRAGUEF TIOH AHMED ET AL.: "Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation and function", CIRCULATION CARDIOVASCULAR INTERVENTIONS, vol. 5, no. 4, 2012, pages 499 - 507 |
E YANGN LIUY TANG ET AL.: "Generation of Neurospheres from human adipose-derived stem cells", BIOMED RES. INT., 2015, pages 743714 |
F COLLADOM POULINJ MURPHY ET AL.: "Patent foramen ovale closure for stroke prevention and other disorders", JAHA, vol. 7e007, 2018, pages 146 |
F JOHNSONK VIRGO: "The bionic human", vol. 07512, 2006, HUMANA PRESS INC, pages: 641 |
F TJONGV REDDY: "Permanent leadless cardiac pacemaker therapy", CIRCULATION, vol. 135, no. 15, 2017, pages 1458 - 7, XP055548443, DOI: 10.1161/CIRCULATIONAHA.116.025037 |
G CASUG GULIZIAG MOLON ET AL.: "ANMCO/AIAC/SICI-GISE/SIC/SICCH consensus document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients:indications, patient selection, staff skills, organization and training", EUROPEAN HEART JOURNAL, vol. 19, 2017, pages D333 - D353 |
G ROSSIA MANFRINM LUTOLF: "Progress and potential in organoid research", NATURE REVIEWS GENETICS, vol. 19, 2018, pages 671 - 687, XP036614286, DOI: 10.1038/s41576-018-0051-9 |
G STONER GAOT KIMURA ET AL.: "1 year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis", LANCET, vol. 387, 2016, pages 1277 - 89, XP029475409, DOI: 10.1016/S0140-6736(15)01039-9 |
J FENG, D NOVIKOV, A ANOUSHIRAVANI, RAN SCHWARZKOPF.: "Total knee arthroplasty: Improving outcomes with a multidisciplinary approach", J MULTIDISCIP HEALTH, vol. 1, no. 1, 2018, pages 63 |
J GALIPEAUL SENSEBE: "Mesenchymal stromal cells:clinical challenges and therapeutic opportunities", CELL STEM CELL, vol. 1-22, no. 6, 2018, pages 824 - 833, XP055607323, DOI: 10.1016/j.stem.2018.05.004 |
J LANE, L PERKINS, A SHEEHY: "Lumen gain and restoration of pulsatility afterimplantation of a bioresorbable vascular scaffold in porcine coronary arteries", CARDIOVASCULAR INTERVENTIONS, vol. 7, no. 6, 2014, pages 688 - 695, XP028855615, DOI: 10.1016/j.jcin.2013.11.024 |
J PEARSON: "Endothelial Progenitor cells-hype or hope?", J THROMB HAEMOST, vol. 7, 2009, pages 255 - 62, XP009160305, DOI: 10.1111/j.1538-7836.2008.03214.x |
K FILARDOG ROFFIA ANDRIOLOL MARCACCI M: "New trends for knee cartilage regeneration: From cell-free scaffolds to mesenchymal stem cells", CURR REV MUSCULOSKELET MED, vol. 5, 2012, pages 236 |
K SUZUKIB MURTUZA N SUZUKIR SMOLENSKIM YACOUB, INTRACORONARY INFUSION OF SKELETAL MYOBLASTS IMPROVES CARDIAC FUNCTION IN DOXORUBICIN-INDUCED HEART FAILURE CIRCULATION, vol. 104, 2001, pages 213 - 217 |
L HEN NGUYENR ARDEHALIB ZHOU: "Heart Regeneration by endogenous stem cells and cardiomyocyte proliferation", CONTROVERSY, FALLACY AND PROGRESS. CIRCULATION, vol. 142, 2020, pages 275 - 291 |
LENARZ: "Chloclear implant-state of the art", GMS CURR TOP OTORHINOLARYGOL HEAD NECK SURG, 2017, pages 16 |
M AYALA GARCIAB YEBRAA LOPEZ FLOREZE GUERRA: "The Major Histocompatibility Complex in transplantation", JOURNAL OF TRANSPLANTATION, 2012, pages 842141 |
M SEIDEL M,A BORCZYNSKA, N ROZWADOWSKA, M KURPISZ: "Cell-based therapyfor heart failure Skeletal myoblasts", CELL TRANSPLANTATION, vol. 18, 2009, pages 695 - 707 |
M SKYLAR-SCOTTS UZELL NAM ET AL.: "Biomanufacturing of organ specific tissues with high cellular density and embedded vascular channels", SCI ADV., vol. 5, 2019, pages 2459 |
MERITXELL HUCHJUERGEN A. KNOBLICHMATTHIAS P. LUTOLFALFONSO MARTINEZ-ARIAS, THE HOPE AND THE HYPE OF ORGANOID RESEARCH DEVELOPMENT, vol. 144, 2017, pages 938 - 941 |
N OHP KAMPAKTSISM GALLO ET AL.: "An updated meta-analysis of MitraClip versus surgery for mitral regurgitation", ANN CARDIOTHORAC SURG, vol. 10, no. 1, 2021, pages 1 - 14 |
P ADLER R FREIM KIMIECIK: "Effects of tube processing on the fatigue life of nitinol", SHAP. MEM. SUPEERELASTICITY, vol. 4, 2018, pages 197 - 217 |
P SERRUYSP DE JAEGEREF KIEMEENEIJ ET AL.: "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease", NEJM, vol. 331, 1994, pages 489 - 495 |
R SCHATZGOLDBERG SM LEON ET AL.: "Clinical experience with the Palmaz-Schatz stent", JACC, vol. 17, no. 6, 1991, pages 155B - 9B |
S AURANGZEBE SHANTZILAG LIPC VARMA: "Endothelial progenitor cells: What use for the cardiologist?", J ANGIOGENESIS RES, vol. 2, no. 1, 2010, pages 6, XP021070688 |
S DHAWANR NANJUNDAPPAJ BRANCHR TAYLOR ET AL.: "Shear stress and plaque development", EXPERT REV CARDIOVASC THER, vol. 8, no. 4, 2010, pages 545 - 556 |
S EZQUERRAA ZULETAR ARANCIBIA ET AL.: "Functional properties of human-derived mesenchymal stem cells spheroids: A meta-analysis and systemic review", STEM CELLS INT, 2021, pages 8825332 |
S FOXO ARANKOJ HEILALAP VAHALA: "Exoskeletons: Comprehensive, comparative and critical analysis of their potential to improve manufacturing performance", J MANUFACTURING TECHNOLOGY MANAGEMENT, vol. 31, no. 6, 2019, pages 1261 - 8 |
S YLA-HERTTUALAC BRIDGESM KATZP KORPISALO: "Angiogenic gene therapy in cardiovascular diseases: dream or vision?", EUROPEAN HEART JOURNAL, vol. 38, 2017, pages 1365 - 1371 |
T CHENF WANGM WUZ WANG: "Development of hematopoietic stem and progenitor cells from human pluripotent stem cells", J CELL BIOCHEM, vol. 116, no. 7, 2015, pages 1179 - 89, XP055290519, DOI: 10.1002/jcb.25097 |
T HENRYLOSORDO DJ TRAVERSER SCHATZ ET AL.: "Autologous CD34 cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials", EUROPEAN HEART J, vol. 39, 2018, pages 2208 - 2216 |
T ICHIMP O'HEERONS KESAN: "Fibroblasts as a practical alternative to mesenchymal stem cells", J TRANSL MED, vol. 16, 2018, pages 212 |
T TSUCHIYAA A SIVARAPATNAK ROCCO ET AL.: "Future prospects for tissue engineered lung transplantation", ORGANOGENESIS, vol. 10, no. 2, 2014, pages 196 - 207 |
TROHMAN RKIM MPINSKI S: "Cardiac pacing: State of the art.", THE LANCET, vol. 364, no. 9446, 2004, pages 1701 - 19, XP005070157, DOI: 10.1016/S0140-6736(04)17358-3 |
V KUMAR, G SANHDU, C HARPER: "Transcatheter aortic valve replacement programs:Clinical outcomes and developments", J AM HEART, 2020, pages 015921 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Warnke et al. | Rapid prototyping: porous titanium alloy scaffolds produced by selective laser melting for bone tissue engineering | |
Han et al. | Porous tantalum and titanium in orthopedics: a review | |
Sarraf et al. | A state-of-the-art review of the fabrication and characteristics of titanium and its alloys for biomedical applications | |
Wilson | Metallic biomaterials: State of the art and new challenges | |
US10463770B2 (en) | Bone tissue engineering by ex vivo stem cells ongrowth into three-dimensional trabecular metal | |
Raut et al. | Biocompatibility of biomaterials for tissue regeneration or replacement | |
Shahali et al. | Recent advances in manufacturing and surface modification of titanium orthopaedic applications | |
Narayan | The next generation of biomaterial development | |
Pei et al. | 3D printed titanium scaffolds with homogeneous diamond-like structures mimicking that of the osteocyte microenvironment and its bone regeneration study | |
Williams | The biomaterials conundrum in tissue engineering | |
Dijkman et al. | Heart valve replacements with regenerative capacity | |
Cheng et al. | Enhanced osteoblast response to porosity and resolution of additively manufactured Ti-6Al-4V constructs with trabeculae-inspired porosity | |
Taghizadeh et al. | Biomaterials in valvular heart diseases | |
Kehl et al. | Bioengineered living cardiac and venous valve replacements: current status and future prospects | |
Amrollahi et al. | Bioreactors for heart valve tissue engineering: a review | |
Jia et al. | Advances in 3D bioprinting technology for functional corneal reconstruction and regeneration | |
CN111921015A (en) | Plasma bionic implantation material and preparation method thereof | |
Özeren et al. | Effect of structural hybrid design on mechanical and biological properties of CoCr scaffolds fabricated by selective laser melting | |
US20220370185A1 (en) | Scaffold for Regenerative Organization of Prosthetic Organ Tissue and Method | |
CN110393610A (en) | Three layers of compound bone implant prosthese of one kind and preparation method thereof | |
WO2023230535A1 (en) | Scaffold for regenerative organization of prosthetic organ tissue and method | |
Mekala et al. | Review on engineering biomaterials in tissue engineering application | |
Baroutaji et al. | Metallic meta-biomaterial as biomedical implants | |
Jana et al. | Leaflet tissue generation from microfibrous heart valve leaflet scaffolds with native characteristics | |
Xu et al. | Recent advances in the design of cardiovascular materials for biomedical applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23757438 Country of ref document: EP Kind code of ref document: A1 |